Zegeye Ephrem Debebe, Diaz Yuleima, Puntervoll Pål
NORCE Norwegian Research Centre, Postboks 22 Nygårdstangen, 5838 Bergen, Norway.
Centre for International Health, Department of Global Public Health and Primary Care, University of Bergen, Postboks 7804, 5020 Bergen, Norway.
Vaccines (Basel). 2022 Feb 4;10(2):241. doi: 10.3390/vaccines10020241.
Heat-stable enterotoxin (ST) producing enterotoxigenic (ETEC) strains are among the top four enteropathogens associated with moderate-to-severe diarrhea in children under five years in low-to-middle income countries, thus making ST a target for an ETEC vaccine. However, ST must be mutated to abolish its enterotoxicity and to prevent a potential immunological cross-reaction due to its structural resemblance to the human peptides uroguanylin and guanylin. To reduce the risk of eliciting cross-reacting antibodies with our lead STh-A14T toxoid, L9 was chosen as an additional mutational target. A double mutant vaccine candidate immunogen, STh-L9A/A14T, was constructed by conjugation to the synthetic virus-like mi3 nanoparticle using the SpyTag/SpyCatcher technology. This immunogen elicited STh neutralizing antibodies in mice, but with less consistency than STh-A14T peptide control immunogens. Moreover, individual sera from mice immunized with both single and double mutant variants displayed varying levels of unwanted cross-reacting antibodies. The lowest levels of cross-reacting antibodies were observed with STh-L9K/A14T control immunogens, suggesting that it is indeed possible to reduce the risk of eliciting cross-reacting antibodies by mutation. However, mutant-specific antibodies were observed for most double mutant immunogens, demonstrating the delicate balancing act between disrupting cross-reacting epitopes, keeping protective ones, and avoiding the formation of neoepitopes.
产热稳定肠毒素(ST)的产肠毒素大肠杆菌(ETEC)菌株是低收入和中等收入国家五岁以下儿童中与中度至重度腹泻相关的四大肠道病原体之一,因此ST成为ETEC疫苗的一个靶点。然而,ST必须发生突变以消除其肠毒性,并防止由于其与人类肽尿鸟苷素和鸟苷素结构相似而产生潜在的免疫交叉反应。为了降低我们的先导STh-A14T类毒素引发交叉反应抗体的风险,选择L9作为额外的突变靶点。使用SpyTag/SpyCatcher技术将双突变疫苗候选免疫原STh-L9A/A14T与合成病毒样mi3纳米颗粒偶联构建而成。这种免疫原在小鼠中引发了STh中和抗体,但一致性不如STh-A14T肽对照免疫原。此外,用单突变和双突变变体免疫的小鼠的个体血清显示出不同水平的不需要的交叉反应抗体。在STh-L9K/A14T对照免疫原中观察到最低水平的交叉反应抗体,这表明通过突变确实有可能降低引发交叉反应抗体的风险。然而,在大多数双突变免疫原中都观察到了突变特异性抗体,这表明在破坏交叉反应表位、保留保护性表位和避免新表位形成之间需要进行微妙的平衡。